Arena Pharmaceuticals (ARNA) Shares are Down -2.99%

Arena Pharmaceuticals (ARNA) : During the past 4 weeks, traders have been relatively bearish on Arena Pharmaceuticals (ARNA), hence the stock is down -3.94% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.96% relative to the S&P 500. The 4-week change in the price of the stock is -3.57% and the stock has fallen -2.99% in the past 1 week.

Arena Pharmaceuticals, Inc. is up 3.18% in the last 3-month period. Year-to-Date the stock performance stands at -14.74%. The stock has recorded a 20-day Moving Average of 3.21% and the 50-Day Moving Average is 6.5%.


Arena Pharmaceuticals (NASDAQ:ARNA): The stock opened at $1.63 on Friday but the bulls could not build on the opening and the stock topped out at $1.67 for the day. The stock traded down to $1.62 during the day, due to lack of any buying support eventually closed down at $1.62 with a loss of -1.22% for the day. The stock had closed at $1.64 on the previous day. The total traded volume was 626,259 shares.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Companys drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development. The Company is exploring lorcaserins once-a-day, extended release formulation, as an aid to smoking cessation, in combination with phentermine and other agents for weight management, and for other possible indications. The Companys other drug candidates include ralinepag for vascular diseases, APD334 for autoimmune diseases, APD371 for pain and fibrotic diseases, and temanogrel for thrombotic diseases.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.